Growth in Estonia's pharma market "to continue"
This article was originally published in Scrip
The Estonian pharmaceutical market may still grow by around 1.3% this year, despite declining in the first half as a result of a general economic downturn, says the Estonia Pharmaceuticals & Healthcare Report Q4 2009 from Business Monitor International. Wholesalers reported sales of EEK747 million ($67 million; -0.5%) in the second quarter; those of prescription drugs fell by 0.2% and of OTC products by 1.6%.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.